{
    "clinical_study": {
        "@rank": "126028", 
        "arm_group": {
            "arm_group_label": "Gemcitabine and nab-Paclitaxel", 
            "arm_group_type": "Experimental", 
            "description": "Gemcitabine (1,000/m2)administered intravenously on days 1 and 15, every 28 days\nnab-Paclitaxel (125mg/m2)administered intravenously on days 1 and 15, every 28 days"
        }, 
        "brief_summary": {
            "textblock": "To determine whether the occurrence of adverse events can be decreased by moving to a\n      bi-weekly schedule of gemcitabine plus nab-Pacitaxel for the treatment of\n      unresectable/metastatic pancreatic cancer."
        }, 
        "brief_title": "Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pancreatic Carcinoma Non-resectable", 
            "Stage IV Pancreatic Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will help determine whether the occurrence of adverse events can be decreased by\n      moving to a bi-weekly, opposed to a weekly dosing schedule of gemcitabine plus nab-Pacitaxel\n      for the treatment of unresectable/metastatic pancreatic cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients must have histologically-proven unresectable/metastatic pancreatic\n             adenocarcinoma.\n\n          2. Patient has one or more radiographically measurable tumor.\n\n          3. Patients may have received prior therapy with gemcitabine alone or with\n             fluoropyrimidines, erlotinib or radiation therapy (RT) in the past.\n\n          4. Age \u2265 18 years.\n\n          5. Patient or legal representative must have read, understood and provided written\n             informed consent and HIPAA authorization after full explanation of the nature of the\n             study.\n\n          6. ECOG performance status 0 - 2 and an expected survival of at least 3 months.\n\n          7. Acceptable hematological parameters within 2 weeks of commencing study therapy as\n             follows:\n\n               -  Absolute neutrophil count (ANC) \u2265 1.5 x 109/L\n\n               -  Platelet count \u2265 100 x 109/L\n\n               -  Hemoglobin (Hgb) \u2265 9g/dl\n\n          8. Patients with adequate organ function as measured by:\n\n             A. Cardiac:  American Heart Association Class I: Patients with cardiac disease but\n             without resulting limitation of physical activity.  Ordinary physical activity does\n             not cause undue fatigue, palpitation, dyspnea, or anginal pain. Hepatic: Bilirubin <\n             2.0 mg/ and ALT and AST < 1.5x the upper limit of normal.\n\n             B. Renal: Creatinine  < 1.5 mg/dl and no other chronic kidney disease.\n\n          9. Women must meet one of the following criteria:\n\n               -  Post-menopausal for at least one year\n\n               -  Surgically incapable of child-bearing\n\n               -  Utilizing a reliable form of contraception for the duration of study\n                  participation.\n\n        Women of child-bearing potential must have a negative serum \u03b2-HCG within 7 days of study\n        drug administration.\n\n        -\n\n        Exclusion Criteria:\n\n          1. Previous use of nab-Paclitaxel for treatment of pancreatic cancer either as\n             monotherapy or combination in neo-adjuvant, adjuvant or the metastatic setting.\n\n          2. Patient has known brain metastases, unless previously treated and well-controlled for\n             at least 3 months (defined as clinically stable, no edema, no steroids and stable in\n             2 scans at least 4 weeks apart).\n\n          3. Other significant active or chronic infection.\n\n          4. History of active other malignancy excluding basal or squamous cell carcinoma of the\n             skin or cervical intraepithelial neoplasia.\n\n          5. Pregnant or nursing females.\n\n          6. Patient has serious medical risk factors involving any of the major organ systems, or\n             serious psychiatric disorders, which could compromise the patient's safety or the\n             study data integrity.\n\n          7. Major surgery, other than diagnostic surgery within 4 weeks of study entry. -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01851174", 
            "org_study_id": "WRMC 12-25"
        }, 
        "intervention": [
            {
                "arm_group_label": "Gemcitabine and nab-Paclitaxel", 
                "description": "Patients will receive Gemcitabine (1,000mg/m2) IV over 30 minutes after nab-paclitaxel infusion", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "Gemzar"
            }, 
            {
                "arm_group_label": "Gemcitabine and nab-Paclitaxel", 
                "description": "Patients will receive nab-Paclitaxel (125mg/m2) IV over 30 minutes before Gemcitabine infusion", 
                "intervention_name": "nab-Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Abraxane"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Goodyear", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85338"
                }, 
                "name": "Western Regional Medical Center"
            }, 
            "investigator": {
                "last_name": "Madappa N. N Kundranda, MD, PHD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study Evaluating Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel in the Treatment of Surgically Unresectable/Metastatic Pancreatic Cancer", 
        "overall_contact": {
            "email": "karen.kohl@ctca-hope.com", 
            "last_name": "Karen V Kohl, RN, CCRC", 
            "phone": "623-207-3000"
        }, 
        "overall_contact_backup": {
            "email": "india.hill@ctca-hope.com", 
            "last_name": "India Hill, CCRP", 
            "phone": "623-207-3000"
        }, 
        "overall_official": {
            "affiliation": "Western Regional Medical Center", 
            "last_name": "Madappa Kundranda, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine the toxicity profile (decrease in hematological and non-hematological treatment-related AE's) with bi-weekly dosing of gemcitabine plus nab-Paclitaxel", 
            "measure": "Overall survival based on toxicity profile of adverse events.", 
            "safety_issue": "Yes", 
            "time_frame": "One year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01851174"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Western Regional Medical Center", 
            "investigator_full_name": "Madappa Kundranda, MD", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Determine progression free survival time with this regimen", 
                "measure": "Progression free survival time", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }, 
            {
                "description": "Determine response rate with this regimen", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }, 
            {
                "description": "Determine duration of response with this regimen", 
                "measure": "Duration of response with this regimen", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }
        ], 
        "source": "Western Regional Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Western Regional Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}